What is ESPR's current stock price?

ESPR (Esperion Therapeutics, Inc.) is currently trading at $3.12 with a market cap of $648.7M.

What sector is Esperion Therapeutics, Inc. in?

Esperion Therapeutics, Inc. (ESPR) operates in the Healthcare sector, specifically in the Biotechnology industry.

Is ESPR a good stock to buy?

Analysts have a Hold consensus on ESPR with a price target of $3.19. Check our detailed analysis for valuation, financials, and insider activity.

InvestLog

ESPR Esperion Therapeutics, Inc.

Healthcare

$3.12-0.32%ClosedMarket Cap: $648.7M

As of 2026-05-26

Valuation

View Details

P/E (TTM)

—

PEG

—

P/B

-2.55

P/S

1.56

EV/EBITDA

9.68

DCF Value

$-67.92

FCF Yield

-2.8%

Div Yield

0.0%

Margins & Returns

Gross Margin

65.0%

Operating Margin

18.1%

Net Margin

-1.8%

ROE

2.0%

ROA

-1.6%

ROIC

46.2%

Financials

View All

Period	Revenue	Net Income	EPS
Q1 null	$80.1M	$-25.2M	$—
Q4 null	$168.4M	$61.8M	$—
FY null	$403.1M	$-22.7M	$—
Q3 null	$87.3M	$-31.3M	$—

Analyst Ratings

View All

Consensus

Hold

Target (Consensus)

$3.19

Target (Median)

$3.16

Target Range

$3.16 - $3.28

3 Strong Buy3 Buy6 Hold0 Sell1 Strong Sell

NeedhamHold

2026-05-04

HC Wainwright & Co.Neutral

2026-05-01

CitizensMarket Outperform

2026-03-13

NeedhamBuy

2026-03-03

HC Wainwright & Co.Buy

2025-09-19

Trading Activity

Insider Trades

View All

Looker Benjaminofficer: Chief Legal Officer

SellWed Mar 18

Koenig Sheldon L.director, officer: President and CEO

SellWed Mar 18

Halladay Benjaminofficer: Chief Financial Officer

SellWed Mar 18

Looker Benjaminofficer: Chief Legal Officer

SellMon Mar 16

Looker Benjaminofficer: Chief Legal Officer

SellMon Mar 16

Company Info

Sector

Healthcare

Industry

Biotechnology

Country

Exchange

—

Beta

0.91

Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascular disease or heterozygous familial hypercholesterolemia. The company has a license and collaboration agreement with Daiichi Sankyo Europe GmbH; and Serometrix to in-license its oral, small molecule PCSK9 inhibitor program. Esperion Therapeutics, Inc. was incorporated in 2008 and is headquartered in Ann Arbor, Michigan.

Peers

EBS